28035391|t|Safety and toxicology of the intravenous administration of Ang2 �€‘ siRNA plasmid chitosan magnetic nanoparticles
28035391|a|This aim of the present study was to investigate the safety and toxicology of intravenous administration of angiopoietin�€‘2 (Ang2)�€‘ small interfering (si)RNA plasmid �€‘ chitosan magnetic nanoparticles (CMNPs). Ang2 �€‘ CMNPs were constructed and subsequently administered at different doses to mice and rats via the tail vein. The acute (in mice) and chronic toxicity (in rats) were observed. The results of the acute toxicity assay revealed that the LD50 mice was >707.0 mg·kg�€‘1·d�€‘1, and the general condition of mice revealed no obvious abnormalities. With the exception of the high dose group (254.6 mg·kg�€‘1·d�€‘1), which exhibited partial lung congestion, the other groups exhibited no obvious abnormalities. Results of the chronic toxicity assay demonstrated that the non�€‘toxic dose of Ang2 �€‘ CMNPs in the rat was >35.35 mg·kg�€‘1·d�€‘1 for 14 days. The rat general condition and blood biochemistry indexes revealed no obvious abnormality. The blood routine indexes and lung/body ratio of each treatment group were higher when compared with the control group. The middle�€‘ and high�€‘dose groups exhibited chronic pulmonary congestion, whilst the low�€‘dose and control groups exhibited no abnormality. Similarly, the other organs revealed no obvious abnormality. Ang2 �€‘ CMNPs have good safety at a certain dose range and may be considered as the target drug carrier.
28035391	0	6	Safety	T080	C0205556
28035391	11	21	toxicology	T091	C0040541
28035391	29	55	intravenous administration	T082	C0013125
28035391	59	63	Ang2	T116,T121	C0540511
28035391	68	73	siRNA	T114,T123	C1099354
28035391	74	81	plasmid	T114,T123	C0032136
28035391	82	90	chitosan	T109,T121	C0162969
28035391	91	113	magnetic nanoparticles	T130	C2713587
28035391	138	143	study	T062	C2603343
28035391	151	162	investigate	T169	C1292732
28035391	167	173	safety	T080	C0205556
28035391	178	188	toxicology	T091	C0040541
28035391	192	218	intravenous administration	T082	C0013125
28035391	222	238	angiopoietin�€‘2	T116,T121	C0540511
28035391	240	244	Ang2	T116,T121	C0540511
28035391	249	274	small interfering (si)RNA	T114,T123	C1099354
28035391	275	282	plasmid	T114,T123	C0032136
28035391	287	295	chitosan	T109,T121	C0162969
28035391	296	318	magnetic nanoparticles	T130	C2713587
28035391	320	325	CMNPs	T130	C2713587
28035391	328	332	Ang2	T116,T121	C0540511
28035391	337	342	CMNPs	T130	C2713587
28035391	377	389	administered	T169	C1521801
28035391	393	402	different	T080	C1705242
28035391	403	408	doses	T081	C0178602
28035391	412	416	mice	T015	C0025929
28035391	421	425	rats	T015	C0034693
28035391	434	443	tail vein	T023	C2985205
28035391	449	454	acute	T079	C0205178
28035391	459	463	mice	T015	C0025929
28035391	469	476	chronic	T079	C0205191
28035391	477	485	toxicity	T037	C0600688
28035391	490	494	rats	T015	C0034693
28035391	501	509	observed	T169	C1441672
28035391	515	522	results	T169	C1274040
28035391	530	535	acute	T079	C0205178
28035391	536	550	toxicity assay	T059	C0022885
28035391	551	559	revealed	T080	C0443289
28035391	569	573	LD50	T081	C0023378
28035391	574	578	mice	T015	C0025929
28035391	615	632	general condition	T033	C1142435
28035391	636	640	mice	T015	C0025929
28035391	641	649	revealed	T080	C0443289
28035391	650	674	no obvious abnormalities	T033	C3809765
28035391	702	711	high dose	T081	C0444956
28035391	712	717	group	T078	C0441833
28035391	749	758	exhibited	T080	C0443289
28035391	759	782	partial lung congestion	T047	C0242073
28035391	794	800	groups	T078	C0441833
28035391	801	810	exhibited	T080	C0443289
28035391	811	835	no obvious abnormalities	T033	C3809765
28035391	852	859	chronic	T079	C0205191
28035391	860	874	toxicity assay	T059	C0022885
28035391	897	908	non�€‘toxic	T080	C1518413
28035391	909	913	dose	T081	C0178602
28035391	917	921	Ang2	T116,T121	C0540511
28035391	926	931	CMNPs	T130	C2713587
28035391	939	942	rat	T015	C0034693
28035391	977	981	days	T079	C0439228
28035391	987	990	rat	T015	C0034693
28035391	991	1008	general condition	T033	C1142435
28035391	1013	1039	blood biochemistry indexes	T059	C1655775
28035391	1040	1048	revealed	T080	C0443289
28035391	1049	1071	no obvious abnormality	T033	C3809765
28035391	1077	1098	blood routine indexes	T059	C0022885
28035391	1103	1118	lung/body ratio	T059	C1261161
28035391	1127	1136	treatment	T169	C1522326
28035391	1137	1142	group	T078	C0441833
28035391	1148	1154	higher	T080	C0205250
28035391	1160	1168	compared	T052	C1707455
28035391	1178	1191	control group	T096	C0009932
28035391	1211	1222	high�€‘dose	T081	C0444956
28035391	1223	1229	groups	T078	C0441833
28035391	1240	1247	chronic	T079	C0205191
28035391	1248	1268	pulmonary congestion	T047	C0242073
28035391	1281	1291	low�€‘dose	T081	C0445550
28035391	1296	1310	control groups	T096	C0009932
28035391	1311	1320	exhibited	T080	C0443289
28035391	1321	1335	no abnormality	T033	C3809765
28035391	1358	1364	organs	T023	C0003055
28035391	1365	1373	revealed	T080	C0443289
28035391	1374	1396	no obvious abnormality	T033	C3809765
28035391	1398	1402	Ang2	T116,T121	C0540511
28035391	1407	1412	CMNPs	T130	C2713587
28035391	1423	1429	safety	T080	C0205556
28035391	1443	1447	dose	T081	C0178602
28035391	1448	1453	range	T081	C1514721
28035391	1465	1475	considered	T078	C0750591
28035391	1483	1489	target	T169	C1521840
28035391	1490	1502	drug carrier	T122	C0013161